NCT04969653|CompletedResults
Loading search results
Sponsor study identifier
observational
754,745
1 country
1
Study Start
June 21, 2021
Actual (reported)Primary Completion
March 31, 2023
Actual (reported)Study Completion
July 1, 2023
Actual (reported)This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 1, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 21, 2021
Actual (reported)July 1, 2021
Actual (reported)July 21, 2021
Actual (reported)March 31, 2023
Actual (reported)July 1, 2023
Actual (reported)December 9, 2024
Actual (reported)Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person.
To describe the risk of venous thromboembolism (composite of pulmonary embolism and deep vein thrombosis) in people with active AD compared to a matched control population.
10 years from index date
Number of Participants With Diagnosis of Pulmonary Embolism After the Start of Follow-up for Each Person
10 years from index date
Number of Participants With Diagnosis of Deep-vein Thrombosis After the Start of Follow-up for Each Person
10 years from index date
All adults with an episode of active atopic dermatitis at any point between 1st Jan 2010 to 1st Jan 2015 will be included for analysis.
Adults without atopic dermatitis or other skin conditions matched to cases by age, gender, and duration of practice registration.
Composite of pulmonary embolism and deep vein thrombosis
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
This study will use routinely collected and collated data from OPCRD to provide a broadly representative sample of the population of the UK.
Contact the study team to confirm eligibility.
Momentum Data Ltd
London, WC1X 8QT, United Kingdom
Warren RB, Basey V, Lynam A, Curtis C, Ardern-Jones MR. The risk of venous thromboembolism in atopic dermatitis: a matched cohort analysis in UK primary care. Br J Dermatol. 2023 Sep 15;189(4):427-436. doi: 10.1093/bjd/ljad212.
Andrew McGovern, MD
Momentum Data Ltd
754,745 participants (actual enrollment reported by the registry).
First Submitted
July 1, 2021
First Posted
July 21, 2021
Study Start
June 21, 2021
Actual (reported)Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
Number of Male Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person
10 years from index date
Number of Female Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person
10 years from index date
Number of Participants Aged 18-44 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person
10 years from index date
Primary Completion
March 31, 2023
Actual (reported)Study Completion
July 1, 2023
Actual (reported)Last Updated
December 9, 2024
Results First Posted
December 9, 2024
Record last verified: 2024-10
OPCRD data can be accessed by bone fide researchers for specific research projects, subject to approval by Anonymised Data Ethics \& Protocol Transparency (ADEPT) Committee. The data utilised for this study cannot be made available without such approval.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: